24/7 Market News- MIRA Pharmaceuticals Reports Preclinical Ketamir-2 Success

July 22, 2024

DENVER, Colo., Jul 22, 2024 (247marketnews.com)- MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) new Ketamir-2 preclinical study results, which continues a string of reported promising preclinical results in recent months for Ketamir-2 as MIRA works towards its goal of submitting an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) by the end of 2024.

Erez Aminov, MRA’s Chairman and CEO, stated, “Our vision at MIRA is to transform the treatment landscape for neurological and neuropsychiatric disorders. Ketamir-2 shows great promise in addressing these debilitating conditions with improved efficacy and safety, offering new hope and better quality of life for patients and their families. Importantly, we are seeing a drumbeat of promising data this year that we hope will allow us to file an IND and begin to test our theories about Ketamir-2 in actual patients in the near term.”

Dr. Itzchak Angel, MRA’s Chief Scientific Advisor, further stated, “Our findings on Ketamir-2 underline its potential as a groundbreaking treatment for mental health disorders. We are committed to advancing Ketamir-2 towards clinical trials and making this innovative treatment available to patients in need.”

MIRA previously predicted that Ketamir-2’s oral bioavailability to be approximately 80%, which significantly higher than traditional ketamine’s less than 30%.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (MIRA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.